What Could a New Study REVEAL About PV Patients?

Published on

Topics include: Treatment and Understanding

As we’ve often learned, clinical studies are the best way to advance medicine and learn more about conditions. In this program, Dr. Ruben Mesa discusses an observational study that is currently enrolling patients with polycythemia vera (PV), one of the myeloproliferative neoplasms. Dr. Mesa explains the purpose of the study, who is eligible, and how the data collected could benefit patients.  To learn more, visit www.revealpvstudy.com

View more programs featuring

Related Programs

ASCO 2015: Discussing Polycythemia Vera Updates with a Roundtable of Experts

As part of our coverage from the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), Patient Power assembled a roundtable discussion with MPN experts, Dr. Ruben Mesa, Dr. Alison Moliterno, Dr. Naveen Pemmaraju and patient advocate Heidi Cascarano to discuss the latest news in polycythemia vera (PV).

Published:

ASH 2014 Coverage: JAK Inhibitor Approved for the Treatment of Polycythemia Vera (PV)

Dr. Ruben Mesa from Mayo Clinic Arizona joined Patient Power to discuss the recent FDA approval of ruxolitinib (Jakafi®) for the treatment of polycythemia vera (PV)—the first medicine approved specifically to treat PV.

Published:

Margo’s Story: Positivity and Hope from an MPN Patient

Margo Sorgman was diagnosed with an MPN, polycythemia vera (PV), just a few months ago at the age of 71. She shares her story of learning about the condition, meeting with Dr. Brady Stein, and how she’s doing today.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on July 2, 2015